Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.
作者信息
Traer E, MacKenzie R, Snead J, Agarwal A, Eiring A M, O'Hare T, Druker B J, Deininger M W
出版信息
Leukemia. 2012 May;26(5):1140-3. doi: 10.1038/leu.2011.325. Epub 2011 Nov 18.
Abstract
摘要
相似文献
1
Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.
Leukemia. 2012 May;26(5):1140-3. doi: 10.1038/leu.2011.325. Epub 2011 Nov 18.
2
Thymoquinone Induces Downregulation of BCR-ABL/JAK/STAT Pathway and Apoptosis in K562 Leukemia Cells.
Asian Pac J Cancer Prev. 2021 Dec 1;22(12):3959-3965. doi: 10.31557/APJCP.2021.22.12.3959.
3
Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.
Oncotarget. 2014 Sep 30;5(18):8637-50. doi: 10.18632/oncotarget.2353.
4
Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.
J Hematol Oncol. 2014 Apr 28;7:37. doi: 10.1186/1756-8722-7-37.
5
Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines.
Acta Haematol. 2014;132(1):75-86. doi: 10.1159/000356784. Epub 2014 Jan 31.
6
ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis.
Leukemia. 2001 Jun;15(6):989-90. doi: 10.1038/sj.leu.2402137.
7
8
miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
Tumour Biol. 2016 Oct;37(10):14117-14128. doi: 10.1007/s13277-016-5205-9. Epub 2016 Aug 12.
9
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
Nat Chem Biol. 2012 Jan 29;8(3):285-93. doi: 10.1038/nchembio.775.
10
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
J Clin Invest. 2013 Oct;123(10):4144-57. doi: 10.1172/JCI68951. Epub 2013 Sep 3.
引用本文的文献
1
Novel treatment strategies for chronic myeloid leukemia.
Blood. 2025 Feb 27;145(9):931-943. doi: 10.1182/blood.2024026312.
2
The prospect of substrate-based kinase inhibitors to improve target selectivity and overcome drug resistance.
Chem Sci. 2024 Jul 13;15(33):13130-13147. doi: 10.1039/d4sc01088d. eCollection 2024 Aug 22.
3
The Role of Cytokines in Activation of Tumour-promoting Pathways and Emergence of Cancer Drug Resistance.
Curr Top Med Chem. 2024;24(6):523-540. doi: 10.2174/0115680266284527240118041129.
4
CXCR2 inhibition overcomes ponatinib intolerance by eradicating chronic myeloid leukemic stem cells through PI3K/Akt/mTOR and dipeptidylpeptidase Ⅳ (CD26).
Heliyon. 2023 Nov 9;9(11):e22091. doi: 10.1016/j.heliyon.2023.e22091. eCollection 2023 Nov.
5
Induction of DNMT1-dependent demethylation of SHP-1 by the natural flavonoid compound Baicalein overcame Imatinib-resistance in CML CD34 cells.
Cell Commun Signal. 2023 Mar 3;21(1):47. doi: 10.1186/s12964-023-01049-9.
6
Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis.
Cancers (Basel). 2021 Sep 28;13(19):4863. doi: 10.3390/cancers13194863.
7
Combinatorial Strategies to Target Molecular and Signaling Pathways to Disarm Cancer Stem Cells.
Front Oncol. 2021 Jul 26;11:689131. doi: 10.3389/fonc.2021.689131. eCollection 2021.
8
Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia.
Pharm Biol. 2021 Dec;59(1):893-903. doi: 10.1080/13880209.2021.1944224.
9
Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?
Int J Mol Sci. 2021 Jun 30;22(13):7093. doi: 10.3390/ijms22137093.
10
Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation.
Front Oncol. 2021 May 13;11:643382. doi: 10.3389/fonc.2021.643382. eCollection 2021.
本文引用的文献
1
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
J Clin Invest. 2011 Jan;121(1):396-409. doi: 10.1172/JCI35721. Epub 2010 Dec 13.
2
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
Lancet Oncol. 2010 Nov;11(11):1029-35. doi: 10.1016/S1470-2045(10)70233-3. Epub 2010 Oct 19.
3
Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML).
Genes Cancer. 2010 Apr;1(4):346-59. doi: 10.1177/1947601910372232.
4
Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors.
Leukemia. 2010 Apr;24(4):771-8. doi: 10.1038/leu.2009.299. Epub 2010 Feb 4.
5
The leukemic stem cell niche: current concepts and therapeutic opportunities.
Blood. 2009 Aug 6;114(6):1150-7. doi: 10.1182/blood-2009-01-202606. Epub 2009 Apr 28.
6
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Leukemia. 2009 Aug;23(8):1441-5. doi: 10.1038/leu.2009.50. Epub 2009 Mar 19.
7
Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance.
Mol Cancer Ther. 2008 Oct;7(10):3169-75. doi: 10.1158/1535-7163.MCT-08-0314.
8
Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.
Mol Cancer Ther. 2008 May;7(5):1121-9. doi: 10.1158/1535-7163.MCT-07-2331. Epub 2008 Apr 29.
9
Hematopoietic cytokine receptor signaling.
Oncogene. 2007 Oct 15;26(47):6724-37. doi: 10.1038/sj.onc.1210757.
10
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Leukemia. 2007 Aug;21(8):1658-68. doi: 10.1038/sj.leu.2404750. Epub 2007 May 31.
Zotero 插件